1ST Biotherappeutics, Inc.

1ST Biotherapeutics is a clinical-stage biotechnology company founded in 2016 that focuses on discovering and developing novel therapeutics for neurodegenerative diseases, immuno-oncology, and rare diseases. The company utilizes its internal expertise and proprietary platform technologies, such as an AI-driven drug discovery engine and a novel antibody-drug conjugate (ADC) payload platform, to advance a portfolio of drug candidates. By leveraging a global R&D network that includes academic institutions, clinical research units, and pharmaceutical industry partners, the company aims to address significant unmet medical needs through rigorous scientific discipline and innovative molecule development.

These research and development efforts are critical to the company's goal of delivering breakthrough therapies to patients. 1ST Biotherapeutics collaborates with major industry players, including clinical trial agreements and pipeline development partnerships, to accelerate its candidates through preclinical and clinical stages. The company's progress is exemplified by programs like its HPK1 inhibitor, which has advanced into clinical trials, and its portfolio of neurodegenerative disease candidates. By engaging in these strategic alliances and maintaining a focus on high-likelihood clinical success, the company provides value to its stakeholders and works toward improving patient outcomes in complex disease areas.